Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | KDM6B | O15054 | 1/20 | 0.52 |
| ▸ | KDM5C | P41229 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.52 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.52 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329761 | 0.86 | KDM4E (0.53) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1331305 | 0.86 | KDM4E (0.50) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1331525 | 0.85 | KDM4E (0.52) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL29707086 | 0.84 | KDM4E (0.60) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL580790 | 0.84 | KDM4E (0.60) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1330582 | 0.82 | KDM4E (0.52) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1329693 | 0.81 | XDH (0.59) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1330018 | 0.81 | KDM4C (0.48) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1329569 | 0.81 | KDM4E (0.47) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL1330071 | 0.81 | JMJD6 (0.48) | KDM4EKDM6BKDM5CKDM4CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426453-B2 | Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid | ASTELLAS PHARMA INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-1932832-B1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7820700-B2 | 2-phenylpyridine derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7816558-B2 | Triarylcarboxylic acid derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-19 | — | — | US | disclosed |
| EP-1783116-B1 | 2-PHENYLPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1932832-A1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1783116-A1 | 2-PHENYLPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275950-A1 | 2-Phenylpyridine Derivative | NLRP3, XDH, UACA | KDM4E 739/4885KDM6B 1150/4885KDM5C 1164/4885 |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | KDM4E 4662/4885KDM6B 3941/4885KDM5C 4440/4885 |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | XDH, NLRP3, UACA | KDM4E 3271/4885KDM6B 2116/4885KDM5C 2703/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | KDM4E 4662/4885KDM6B 3941/4885KDM5C 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.